American Regent, Inc. – FDA 483, Jan 25, 2019
HBT Labs, Inc. in Brea, CA, underwent an FDA inspection from January 7-25, 2019, regarding its manufacturing of Paclitaxel Albumin Bound Bulk Suspension. The inspection revealed significant deficiencies across multiple areas, including inadequate method validation, data integrity issues, incomplete batch and master production records, lack of written procedures for critical processes, and failures in quality control unit responsibilities and supplier qualification. These findings indicate a broad lack of adherence to cGMP requirements, posing potential risks to drug product quality and purity.
ID · 53bc2bb3-5c5f-464c-8d61-1a04e622d4f7
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.